- Home
- VERI vs IMUX Comparison
VERI vs IMUX Comparison
Compare VERI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERI | IMUX |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.9M | 152.6M |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VERI | IMUX |
|---|---|---|
| Price | $2.17 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $7.00 | $4.50 |
| AVG Volume (30 Days) | ★ 3.3M | 2.6M |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,637,000.00 | N/A |
| Revenue This Year | $52.20 | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.29 | $0.51 |
| 52 Week High | $9.42 | $1.51 |
Technical Indicators
Market Signals| Indicator | VERI | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 37.09 |
| Support Level | $1.78 | $0.78 |
| Resistance Level | $3.19 | $1.17 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 48.59 | 9.78 |
Price Performance
Historical ComparisonAbout VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel, and India.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.